Intratumoral Modulation Therapy Cuts Rat Glioblastoma Growth Eightfold in Preclinical Test

The team implanted electrodes into rat brains bearing U87 or patient-derived glioblastoma cells and delivered spatiotemporally patterned fields at frequencies above those used for deep-brain stimulation. This approach avoided motor side effects while targeting mitotic spindle assembly in rapidly dividing tumor cells. Tumor burden was tracked daily by bioluminescence and confirmed at endpoint by T2-weighted MRI and histology.

Relative to sham controls, treated animals showed median tumor-volume growth of 12 % versus 96 % on MRI; bioluminescent flux rose 2.3-fold versus 18-fold. The study builds on Tumor Treating Fields (TTFields) data from the EF-14 trial yet differs by using focal, implantable delivery rather than extracranial arrays, potentially allowing higher local intensity with lower whole-brain exposure.

Current glioblastoma median survival remains 12–15 months after maximal surgery, temozolomide and radiation. IMT’s ability to be combined with existing standards without added systemic toxicity is attractive, but the rat model lacks human skull thickness, immune infiltration and long-term field tolerance data. Next steps require GLP safety studies in larger animals before an investigational-device exemption submission.

Human translation will hinge on demonstrating that chronic electrode implantation does not increase infection risk or induce seizures above baseline rates seen with deep-brain stimulators.